| 产品编号 | bs-42263P |
| 英文名称 | Recombinant human HER2 protein, N-His |
| 中文名称 | 重组人HER2蛋白 |
| 别 名 | erbB-2 isoform 2; HER2 receptor; Erbb2 protein; CerbB2; c erb B2; C erbB 2; C-erbB2; CD340; Erb B2; erbb2; HER 2; Her-2; HER 2/neu; Her2/neu; Herstatin; MLN 19; MLN19; NEU; NEU Proto Oncogene; Neuro Glioblastoma Derived Oncogene Homolog; NGL; p185 ErbB2; |
| 理论分子量 | 40.7 kDa |
| 检测分子量 | |
| 性 状 | Lyophilized or Liquid |
| 浓 度 | >1mg/ml |
| 物 种 | Human |
| 序 列 | 23-372/1255 |
| 纯 度 | >90% as determined by SDS-PAGE |
| 纯化方法 | AC |
| 内毒素 | Not analyzed |
| 表达系统 | E.coli |
| 标签 | N-His |
| 缓 冲 液 | 20mM Tris-HCl (pH8.0) with 8M Urea and 1mM DTT. |
| 保存条件 | Stored at -70℃ or -20℃. Avoid repeated freeze/thaw cycles. |
| 注意事项 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| 产品介绍 |
This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized. [provided by RefSeq, Jul 2008]. SWISS: P04626 Gene ID: 2064 细胞膜受体（Membrane Receptors) c-erbB-2癌基因，在很多癌组织中呈C-erbB-2过度表达。cerbB尤其临床常用于乳腺癌术后C-erbB-2蛋白、雌激素受体（ER）和孕激素受体（PR）表达情况，旨在进一步探讨癌基因蛋白，细胞增殖活性和激素受体与乳腺癌组织学分级及术后生存期的关系，为乳腺癌的病理诊断、预后判断及治疗提供依据。 |
| 产品图片 |
The purity of the protein is greater than 90% as determined by reducing SDS-PAGE.
|
| 1、抗体溶解方法 | |
| 2、抗体修复方式 | |
| 3、常用试剂的配制 | |
| 4、免疫组化操作步骤 | |
| 5、免疫组化问题解答 | |
| 6、Western Blotting 操作步骤 | |
| 7、Western Blotting 问题解答 | |
| 8、关于肽链的设计 | |
| 9、多肽的溶解与保存 | |
| 10、酶标抗体效价测定程序 | |
